Status and phase
Conditions
Treatments
About
Full description
Efficacy evaluation:
Primary efficacy index:
After 12 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality groups, comparing with the base line information
Secondary efficacy index:
After 8 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality groups, comparing with the base line information
Safety evaluation:
Adverse Event Vital Sign and Physical Examination 12-lead ECG Laboratory Tests (including blood routine examination, routine urine analysis, blood biochemistry examination, glycosylated hemoglobin)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
40~75-year-old male or female
Clarified diagnosis of type 2 diabetes mellitus
Arteriosclerosis obliterans (ASO) is diagnosed (ASO diagnoses should meet at least one of the conditions as below:
Informed Consent Form Signature
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal